Home · Healthcare M&A · Sell a Cardiology Practice in NJ
Specialty Practice M&A · 2026
Cardiology is one of the most actively-consolidated medical specialties in New Jersey in 2026, driven by PE-backed cardiology platforms aggressively building regional groups and hospital systems competing for site-of-service shifts. NJ cardiology practices with $2M+ EBITDA, in-office ancillaries (echo, stress testing, vascular), and clean payer mix consistently command premium multiples. We've represented NJ cardiology practices in single-physician transitions, multi-physician group sales, and PE-platform roll-ins.
NJ cardiology practices typically sell at 5×–8× EBITDA. The high end is driven by in-office echo and stress testing ancillaries, vascular lab, cardiac CT, hospital-system contracts, Medicare Advantage panel concentration, and multi-physician group structures.
| Sub-specialty / Category | Typical Multiple |
|---|---|
| General cardiology with ancillaries | 5×–7× EBITDA — strongest segment for PE buyer competition |
| Interventional cardiology (cath lab privileges) | 6×–8× EBITDA — high-value because of cath lab volume |
| Electrophysiology | 6×–9× EBITDA — specialized, fewer PE platforms compete but premium when matched |
| Heart failure / advanced HF | Lower multiples standalone; higher when bundled with general cardiology |
| Pediatric cardiology | Specialty platform interest limited; hospital-system MSOs are primary buyers |
Cardiology M&A in NJ runs through standard CPOM compliance — non-physician PE investors structure deals as MSO/Friendly-PC where the cardiologists own the PC and the PE platform owns the management services entity. Stark Law compliance is critical given cardiology's frequent referral relationships (echo, cath, lab) — the deal structure must include written FMV agreements for referral-eligible services. NJ Board of Medical Examiners license transitions are routine. NY State cardiology practices with imaging centers operating under Article 28 require PHHPC CON for ownership changes.
NJ cardiology practices typically sell at 5×–8× EBITDA. General cardiology with in-office ancillaries (echo, stress testing) trades at 5×–7×. Interventional cardiology with cath lab privileges trades at 6×–8×. Electrophysiology can reach 9×. Solo practices without ancillaries trade lower.
US Cardiology Partners (Ares-backed), Cardiovascular Associates of America (Webster Equity), Pinnacle Healthcare Partners, plus several regional NJ-NY hospital system MSOs (RWJBarnabas, Hackensack Meridian, Atlantic Health). PE auction processes for premium NJ cardiology groups typically produce 3–6 competing LOIs.
Typical NJ cardiology practice sales close in 8–12 months. PE-platform transactions add 1–2 months for QoE and integration planning. Sales involving imaging centers operating under NY Article 28 add 6–12 months for PHHPC CON approval.
Almost always yes. PE buyers expect selling cardiologists to commit to 2–3 years of post-close practice continuity, typically at 28–35% of personal collections. Rollover equity (typically 20–30%) participates in the PE platform's eventual exit, creating upside above the cash-at-close component.
No. Success-only commission. You pay nothing until your practice sells.
Schedule a free confidential 30-minute conversation. We'll review your practice profile, give you a realistic valuation range, and tell you which PE platforms or strategic acquirers fit your specific situation. $0 upfront, no obligation.
Related: Healthcare M&A NJ pillar · Sell a Medical Practice · Sell an ASC · Quality of Earnings Guide